Medication info
Innoen Abeltan Plus Tablet 150/12.5 mg

Innoen Abeltan Plus Tablet 150/12.5 mg

Prescription medicationTabletOral
Ingredient · strength
Irbesartan›150mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
HK Innoen Co., Ltd.
Appearance
Pink, oval, biconvex film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201005699 · Notified 2010.09.28 · Insurance code 640005850

Summary

Main use
Treatment of hypertension when control with monotherapy is inadequate or initial combination therapy is required
Who takes it
Adults · Children
Adult dose
This medicine is administered once daily, regardless of meals. It is recommended that the appropriate dose of each ingredient (irbesartan and hydrochlorothiazide) be determined. ○ Adults 1. Patients whose blood pressure is not adequately controlled with monotherapy - Administer one tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 150 mg or hydrochlorothiazide alone. - Administer one tablet of irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg. - Administer one tablet of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 300 mg/hydrochlorothiazide 12.5 mg. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. If necessary, this medicine may be administered in combination with other antihypertensive agents. 2. When considering this medicine as initial therapy for patients with moderate or severe hypertension (stage 2), treatment should be individualized, taking into account baseline blood pressure, the target blood pressure, and the expected increase in the likelihood of reaching the treatment target compared with monotherapy. Treatment is generally initiated with one tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily; if blood pressure control is needed, the dose may be increased after 1 ~ 2 weeks to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg. Use of this medicine as initial therapy is not recommended in patients with intravascular volume depletion. ○ Patients with renal impairment Because of the hydrochlorothiazide component, this medicine is not recommended in patients with severe renal impairment (creatinine clearance〈 30 mL/min). Loop diuretics are preferred for this patient population. No dose adjustment is necessary in patients with renal impairment whose creatinine clearance is 30 mL/min or higher. ○ Patients with volume depletion If sodium and/or fluid depletion is present, correct the imbalance before administering this medicine. ○ Patients with hepatic impairment This medicine should not be used in patients with severe hepatic impairment. Thiazide drugs should be used with caution in patients with hepatic impairment. No dose adjustment is necessary in patients with mild ~ moderate hepatic impairment. ○ Elderly patients No dose adjustment is necessary for elderly patients.
Child dose
○ Pediatric patients The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
HK Innoen Co., Ltd.

Efficacy & effects

Treatment of hypertension when control with monotherapy is inadequate or initial combination therapy is required

  • Hypertension
View approved original text

This medication assists patients whose blood pressure is not sufficiently controlled by monotherapy and is used as initial therapy in cases where combination treatment with multiple medications is needed to achieve the target blood pressure in patients with moderate to severe hypertension. This ultimately improves blood pressure control and helps reduce the risk of cardiovascular complications.

How to take

Adult dose

This medicine is administered once daily, regardless of meals. It is recommended that the appropriate dose of each ingredient (irbesartan and hydrochlorothiazide) be determined. ○ Adults 1. Patients whose blood pressure is not adequately controlled with monotherapy - Administer one tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 150 mg or hydrochlorothiazide alone. - Administer one tablet of irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg. - Administer one tablet of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 300 mg/hydrochlorothiazide 12.5 mg. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. If necessary, this medicine may be administered in combination with other antihypertensive agents. 2. When considering this medicine as initial therapy for patients with moderate or severe hypertension (stage 2), treatment should be individualized, taking into account baseline blood pressure, the target blood pressure, and the expected increase in the likelihood of reaching the treatment target compared with monotherapy. Treatment is generally initiated with one tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily; if blood pressure control is needed, the dose may be increased after 1 ~ 2 weeks to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg. Use of this medicine as initial therapy is not recommended in patients with intravascular volume depletion. ○ Patients with renal impairment Because of the hydrochlorothiazide component, this medicine is not recommended in patients with severe renal impairment (creatinine clearance〈 30 mL/min). Loop diuretics are preferred for this patient population. No dose adjustment is necessary in patients with renal impairment whose creatinine clearance is 30 mL/min or higher. ○ Patients with volume depletion If sodium and/or fluid depletion is present, correct the imbalance before administering this medicine. ○ Patients with hepatic impairment This medicine should not be used in patients with severe hepatic impairment. Thiazide drugs should be used with caution in patients with hepatic impairment. No dose adjustment is necessary in patients with mild ~ moderate hepatic impairment. ○ Elderly patients No dose adjustment is necessary for elderly patients.

Child dose

○ Pediatric patients The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.

Precautions

This medication should not be administered to pregnant women or women who might become pregnant, as taking it during pregnancy may pose a risk of serious harm or death to the fetus or newborn. Do not use if there is a history of allergic reactions or hypersensitivity to the ingredients in this medication or similar medications. Administration should be avoided in patients with severely impaired kidney function or anuria. Patients with severely impaired liver function or specific liver diseases should not use this medication. Patients with a history of angioedema (swelling of the blood vessels) or those who have experienced angioedema after taking similar medications should use caution. Patients with hypotension, reduced blood volume, renal artery stenosis, kidney transplant patients, liver disease patients, and patients with heart valve disease should use this medication with caution. The diuretic component in this medication may increase sensitivity to sunlight, potentially raising the risk of skin cancer; therefore, limiting sun exposure and taking protective measures during treatment is advised. Side effects such as dizziness, fatigue, nausea, vomiting, and abnormal urination may occur, so consult a doctor if symptoms are severe. Caution is required when driving or operating machinery as dizziness or fatigue can occur. In cases of hypotension risk, it is essential to manage the loss of fluids and electrolytes due to inadequate salt intake, excessive diuretic use, diarrhea, or vomiting. Diabetic patients may be affected in terms of blood sugar control, so check blood glucose levels regularly and dosage adjustments may be necessary. Regular blood tests are needed as electrolyte imbalances (especially potassium, sodium, magnesium, etc.) may occur; caution is needed when taken alongside potassium supplements or potassium-lowering medications. Patients with a history of eye diseases such as acute angle-closure glaucoma should seek immediate treatment if vision changes or eye pain occurs after taking this medication. There may be interactions when taken with other antihypertensive medications; therefore, inform your doctor or pharmacist if you are taking any other medication. Caution against concomitant use with lithium preparations is advised due to the risk of lithium toxicity. This medication is not recommended for breastfeeding women and should not be used while nursing. Safety for children and adolescents has not been established, so the use in these populations is not recommended. For elderly patients, dosage adjustment or monitoring may be necessary due to different sensitivities. In case of overdose, symptoms of hypotension, electrolyte abnormalities, and dehydration may appear, requiring immediate medical attention.

Side effects

  • dizziness
  • fatigue
  • nausea
  • vomiting
  • abnormal urination
  • elevated BUN
  • elevated creatine kinase
  • elevated creatinine
  • orthostatic dizziness
  • headache
Show 79 more
  • syncope
  • hypotension
  • tachycardia
  • edema
  • flushing
  • cough
  • diarrhea
  • dyspepsia
  • taste alteration
  • jaundice
  • hepatitis
  • abnormal liver function
  • sexual dysfunction
  • change in libido
  • renal impairment
  • limb edema
  • arthralgia
  • myalgia
  • tinnitus
  • angioedema
  • rash
  • urticaria
  • hyperkalemia
  • decreased serum potassium
  • decreased serum sodium
  • hypotension
  • shingles
  • colon cancer
  • hematoma
  • anaphylactic shock
  • anaphylactic reaction
  • intestinal angioedema
  • anemia
  • thrombocytopenia
  • hypoglycemia
  • depression
  • sleep disturbances
  • orthostatic hypotension
  • arrhythmia
  • aplastic anemia
  • bone marrow suppression
  • neutropenia
  • agranulocytosis
  • hemolytic anemia
  • leukopenia
  • thrombocytopenia
  • respiratory distress
  • pancreatitis
  • loss of appetite
  • constipation
  • gastric irritation
  • sialadenitis
  • loss of appetite
  • interstitial nephritis
  • renal dysfunction
  • jaundice
  • transient blurred vision
  • xanthopsia
  • weakness
  • muscle spasms
  • anaphylactoid reaction
  • toxic epidermal necrolysis
  • necrotizing vasculitis
  • lupus-like erythema multiforme reaction
  • reactivation of lupus erythema
  • photosensitivity reaction
  • rash
  • urticaria
  • fever
  • electrolyte imbalance
  • hyperuricemia
  • diabetes
  • hyperglycemia
  • elevated cholesterol
  • elevated triglycerides
  • hypokalemia
  • hyponatremia
  • muscle cramps
  • bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, it is best stored at room temperature between 1 and 30 degrees Celsius, avoiding extremes of temperature.

Appearance and packaging

Appearance

Pink, oval, biconvex film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.